Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Arkuda Therapeutics logo — Discovering therapies to change the trajectory of neurodegen...

Arkuda Therapeutics

Discovering therapies to change the trajectory of neurodegenerative disease

Founded 2018 United States Watertown, United States 18 employees Series B Total: $108.00M Biotechnology, Health Care +2

General Information

Company Name Arkuda Therapeutics
Founded Year 2018
Location United States Watertown, United States +1
Employees 18
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series B
Social

Get notified when Arkuda Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company founded in 2018 and headquartered in the United States. The company's slogan, "Discovering therapies to change the trajectory of neurodegenerative disease," reflects its focus on leveraging new insights into progranulin and lysosomal biology to develop medicines for neurodegenerative diseases. In its latest funding round in February 2022, Arkuda Therapeutics secured a substantial $64.00M Series B investment. This funding was supported by an impressive group of investors including Atlas Venture, Pivotal bioVenture Partners, Cormorant Asset Management, Eli Lilly, Mission BioCapital, Tekla Capital, Pfizer Venture Investments, and Surveyor Capital. Arkuda Therapeutics' innovative approach to tackling neurodegenerative diseases, coupled with the strong support from renowned investors, positions the company as a promising player in the biotechnology, healthcare, and pharmaceutical industries. By targeting a pressing medical need with a novel therapeutic approach, Arkuda Therapeutics demonstrates significant potential for future growth and impact on addressing neurodegenerative diseases.

Taxonomy: neurodegenerative disease, therapies, progranulin, lysosomal biology, medicine development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 8
Investor Investor Investor Investor Investor
•••• •••• 		10 Feb 2022
Grant •••••• 1
Investor
06 Dec 2021
Series A •••••• 1 •••• •••• 07 Nov 2019

FAQ About Arkuda Therapeutics

Discovering therapies to change the trajectory of neurodegenerative disease
Arkuda Therapeutics was founded in 2018.
Arkuda Therapeutics is headquartered in Watertown, United States.
Arkuda Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.
Arkuda Therapeutics has approximately 18 employees.
Arkuda Therapeutics has completed 3 funding rounds, raising a total of $108.00M. The latest funding stage is Series B.

We're actively collecting intelligence on Arkuda Therapeutics.

Track Arkuda Therapeutics to get notified

Don't just browse. Track.

Signal Tracker monitors Arkuda Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy